Showing 2762 results
- Media Release /Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compared to valsartan1 Entresto, compared to valsartan, demonstrated…
- Media Release /With more than 140 abstracts, Novartis continues its leadership in hematology innovation Data for MBG453, an innovative anti-TIM-3 immunotherapy, with decitabine on preliminary response rates in…
- Key Release /Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL…
- Key Release /Basel, August 14, 2018 - Novartis announced today the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and…
- Key Release /SOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on or following treatment with an aromatase…
- Media Release /Die Zulassung durch die EK basiert auf den ersten globalen CAR-T-Zulassungsstudien, an denen Patienten aus acht europäischen Ländern teilnahmen und die ein dauerhaftes Ansprechen und ein…
- Media Release /TRANSITION shows that Entresto can be safely initiated shortly after an acute heart failure episode, both in the hospital and in an out-patient setting and in a wide range of stabilized patients[1…
- Media Release /The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in…
- Key Release /Decision based on five-year data from COMPASS-XT long-term safety study Alcon advises ophthalmic surgeons to cease further implantation Basel, August 29, 2018 - Reflecting its uncompromising…
- Media Release /Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients More than 50% of stage III melanoma…
Pagination
- ‹ Previous page
- 1
- …
- 188
- 189
- 190
- 191
- 192
- 193
- 194
- …
- 277
- › Next page